All companies
Visit website
CORVIDANE
OperatingBurke and Boyer, Inc.
Healthcare · Technology · Founded 2014
Black-founded
Developing a novel, safe drug to prevent heart attacks, strokes and liver transplants for NASH
Valuation cap ⓘ
$21.0M
As of Oct 2023 · from CORVIDANE Future Equity SAFE 2 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$372,034
Across 2 rounds since 2022
Latest share price
$1.00
CORVIDANE Future Equity SAFE 2 offering price
Financials
FY2019–FY2022 · from SEC filings · hover any figure for its source$0
−$40K
2019
$0
−$34K
2020
$0
−$95K
2021
$0
−$182K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
FY2022
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
Net income
-$39,724
-$33,665
-$94,859
-$182,267
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$12,851
$2,738
$0
$58,779
Accounts receivable
$0
$0
$0
$0
Total assets
$67,875
$69,379
$200,058
$287,265
Short-term debt
$64,755
$80,607
$289,392
$549,807
Long-term debt
$0
$0
$0
$0
Total liabilities
$64,755
$80,607
$289,392
$549,807
Other
Headcount
—
3
—
3
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$20.0M
Valuation cap
$21.0M
Valuation cap
CORVIDANE Future Equity SAFE 1
CORVIDANE Future Equity SAFE 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $750 / $618KValuation cap $21M
Raised $371.3K / $1MInvestors 229Valuation cap $20M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 5 annual reports (FY2021–FY2025)
229 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001902393Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.